CONTEXT:Sodium benzoate is mainly used as a preservative in food and pharmaceuticals and as a treatment for hyperammonemia in urea-cycle disorders. It is typically diluted in 5 or 10% dextrose solutions for intravenous administration to patients. While the stability of oral and injectable sodium benzoate formulations has been studied, there is limited research on its stability as an injectable solution under International Council for Harmonisation (ICH) conditions. AIM:This study evaluates the stability of a sodium benzoate injectable formulation in sterile water (100 mg/mL). METHODS:A 100 mg/mL sodium benzoate solution was prepared in sterile water. A highperformance liquid chromatography method with UV detection (HPLC-UV) was developed for dosage measurement. The solution was stored in sterile glass bottles at room temperature (25°C) and under refrigeration (5°C). The effects of plastic and rubber screw caps on stability were also assessed. Stability was monitored over 230 days using validated HPLC-UV methods, and microbiological assays were performed to ensure sterility per USP <797> and USP <81> standards, as required by the "Ordre des pharmaciens du Québec." RESULTS:Sodium benzoate preparations in 10-mL horizontal and inverted glass bottles remained stable for at least 230 days at both storage conditions. CONCLUSIONS:Sodium benzoate injectable preparations can be stored safely for 230 days at both room temperature and under refrigeration, maintaining efficacy and safety for intravenous patient administration. However, microbiological and endotoxin testing are necessary for each batch to ensure continued safety and effectiveness, according with the Quebec sterile production standard OPQ 2014.01.
This study evaluated the chemical and microbiological stability of six oral liquid formulations, benazepril hydrochloride, candesartan cilexetil, disulfiram, fluconazole, methocarbamol, and pentoxifylline, compounded in the suspending vehicle SyrSpend® SF PH4. Stability-indicating UHPLC methods were validated for each API and confirmed to be specific, precise, accurate, and linear within the analytical ranges tested. Forced degradation studies ensured method suitability for detecting potential decomposition pathways. Chemical stability was assessed over 90 days under room temperature and refrigerated storage, alongside pH monitoring and visual inspection. Antimicrobial effectiveness testing (USP <51>, Category 3: oral aqueous products) demonstrated that all formulations met preservative efficacy criteria at the final assigned BUD. Results revealed API-specific stability profiles: several formulations remained within 90-110% of label claim for up to 90 days, while others showed temperature degradation patterns dictating shorter BUDs. Overall, SyrSpend® SF PH4 proved to be a versatile and reliable vehicle for compounded oral liquids, supporting extended BUDs while maintaining physicochemical integrity and microbiological quality. These findings reveal dependent degradation patterns that dictate shorter BUDs. Overall, SyrSpend® SF PH4 proved to be a versatile and reliable vehicle for compounded oral liquids, supporting extended BUDs while preserving physicochemical integrity and microbiological quality. These findings provide evidence-based guidance for compounding pharmacists and reinforce the role of SyrSpend® SF PH4 in personalized pharmacotherapy.
Supplier and material qualifications are one of the least visible, but most critical, elements of a 503B outsourcing facility's quality system. When it works well, it attracts little attention. When it breaks down, the consequences often appear in the areas FDA consistently evaluates production and process controls, sterility assurance, labeling controls, and patient safety. A quality maturity lens makes this topic practical. It helps leaders distinguish between having procedures on paper and having controls that function reliably in day to day operations. That perspective aligns with the principles reflected in FDA's Quality Management Maturity (QMM) initiative, which encourages manufacturers to move beyond baseline CGMP compliance toward systems that are proactive, resilient, and continuously improving. Although FDA's QMM program has been developed primarily in conventional pharmaceutical manufacturing, its core concepts, management commitment to quality, effective supply chain oversight, risk based decision making, and meaningful management review, translate directly to supplier and material control expectations relevant to 503B outsourcing facilities.1,2.
BACKGROUND:Antioxidants protect the skin from free radicals, which are associated with signs of aging, pigmentation, and loss of elasticity. Combining antioxidants in cosmetic formulations may provide broader antioxidant potential. This study focuses on the formulation and optimization of a polyherbal antioxidant peel-off mask using extracts of Ocimum sanctum (Tulsi), Moringa oleifera (Moringa), and Trigonella foenum-graecum (Fenugreek), which are reported to possess antioxidant and skin-beneficial properties. METHODOLOGY:The formulation and optimization of the polyherbal peel-off mask were carried out using Central Composite Design (CCD). Polyvinyl alcohol (PVA) and carbomer 940 served as film-forming agents, while triethanolamine was used to adjust viscosity. The optimized formulation was evaluated for physicochemical characteristics, in vitro antioxidant activity, and irritation potential using the HET-CAM assay. RESULTS:The optimized formulation exhibited a drying time of 25.3 minutes and an applicability score of 18.82. Physicochemical evaluation showed acceptable homogeneity, smooth texture, and pH suitable for topical application. In vitro antioxidant assays demonstrated a lower IC50 value for the polyherbal mask compared to the standard vitamin C formulation, indicating notable antioxidant activity. Furthermore, the CAM (chorio-allantoic membrane) irritation test showed no observable signs of irritation such as hemorrhage, lysis, or coagulation under the study conditions. CONCLUSION:This study successfully formulated and optimized a polyherbal peel-off mask with promising in vitro antioxidant activity and acceptable physicochemical characteristics. The use of Central Composite Design (CCD) enabled systematic optimization of the formulation variables. The findings suggest the potential applicability of the developed herbal formulation for cosmetic skincare applications; however, further stability studies and in vivo safety and efficacy evaluations are required.
